PREPARATION AND IN VITRO EVALUATION OF CANDESARTAN CILEXETIL–BASED NANOPARTICLES AS FAST DISSOLVING ORAL FILM
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56372Keywords:
Candesartan nanoparticle, Fast dissolving film, Solubility, In vitro releaseAbstract
Objective: The present work aims to formulate candesartan cilexetil (CC) as nanoparticles oral film to enhance solubility of CC, and promote its dissolution rate, and this could produce rapid therapeutic action of drug.
Methods: The nanoparticles prepared by solvent/antisolvent precipitated method then formulated as fast dissolving oral films by casting method.CC nanoparticles formulated by different polymer: drug ratio which was 1:1 and 2:1 hydroxypropyl methylcellulose (HPMC), and polyvinylpyrrolidone (PVP) with different molecular weight like, HPMCE5, HPMCE50, PVPK15 and PVPK30. The effect of polymer type, polymer ratio and injected volume on the size and specific surface area of prepared particle were tested.
Results: The bested formula FCC3 was found with a smallest size equal to 37 nm and specific surface area of 54.66m2/g. The FCC3 formula was dried by freeze drier and tested by field emission scanning electron microscope (FESEM), differential scanning calorimetry (DSC) and X-ray powder diffraction analysis (XRD) to determine surface morphology, crystallinity and compatibility, then formulated as fast dissolving oral film. The drug content in the 4 cm2 prepared film was distributed between 93.00% ± 1.75 to 98.25% ± 1.25 and disintegrate in 25min. The in vitro release of candesartan nanoparticle from oral film was 68% in 2 minute and complete to 100% at 4 minutes.
Conclusion: The results confirmed fast release and better dissolution rate of prepared candesartan nanoparticle than pure drug.
References
1. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013 Jan;65(1):315-499. doi: 10.1124/pr.112.005660. PMID: 23383426.
2. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines. 2022 Aug 23;10(9):2055. doi: 10.3390/biomedicines10092055. PMID: 36140156; PMCID: PMC9495787.
3. Vijayaraj S, Omshanthi B, Anitha S, Kumar KPS. Synthesis and characterization of novel sulphoxide prodrug of famotidine. Indian J Pharm Educ Res. 2014 Oct;48(4):35-44. doi: 10.5530/ijper.48.4.6.
4. Da Silva FLO, Marques MBF, Kato KC, Carneiro G. Nanonization techniques to overcome poor water-solubility with drugs. Expert Opin Drug Discov. 2020 Jul;15(7):853-864. doi: 10.1080/17460441.2020.1750591. Epub 2020 Apr 15. PMID: 32290727.
5. Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajkó R, Szabó-Révész P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm. 2009 Nov 3;381(2):153-9. doi: 10.1016/j.ijpharm.2009.07.009. Epub 2009 Jul 17. PMID: 19616609.
6. Kawale KA, Autade NB, Narhare HS, Mhetre RL. A review on fast-dissolving oral film. Asian J Pharm Clin Res. 2023 Oct;16(10):7-17. doi: 10.22159/ajpcr.2023.v16i10.48099.
7. Asif H, Sabir A, Moloy M, Parminder S, Bhasin A. Review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharm Sci. 2011 Dec;1(10):12-7.
8. Shaikh SM, Avachat AM. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions. Curr Drug Deliv. 2011 Jul;8(4):346-53. doi: 10.2174/156720111795767997. PMID: 21453263.
9. Vairappan K, Ayarivan P, Lakshmanan R, and Sundaravadivelu J. Development and Validation of A Dissolution Test with Reversed-Phase High Performance Liquid chromatographic Analysis for Candesartan Cilexetil in Tablet Dosage Forms. Arabian J. Chem.. 2011: 67-78. doi.org/10.1016/J.ARABJC.2011.09.011
10. Sweetman S, editor. Martindale: The complete drug reference. 36th ed. London (UK): Pharmaceutical Press; 2009.
11. Wu CY, Wang W. Application of Antisolvent Precipitation Method for Formulating Excipient-Free Nanoparticles of Psychotropic Drugs. Pharmaceutics. 2022 Apr 8;14(4):819. doi: 10.3390/pharmaceutics14040819. PMID: 35456653; PMCID: PMC9029518.
12. Paudel A, Ameeduzzafar, Imam SS, Fazil M, Khan S, Hafeez A, Ahmad FJ, Ali A. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. Curr Drug Deliv. 2017;14(7):1005-1015. doi: 10.2174/1567201813666161230141717. PMID: 28034361.
13. Reddy E. Enhancement of candesartan cilexetil by self emulsifying drug delivery system. Int J Pharm Sci Res. 2012 Jul;3(7):2098-104. doi: 10.13040/IJPSR.0975-8232.3(7).2098-04.
14. Keshari A, Sharma PK, Parvez N. Fast dissolving oral film: a novel and innovative drug delivery system. Int J Pharm Sci Res. 2014 Mar;5:92-5.
15. Bawane S, Teirandhe R, Pande SD. Formulation and evaluation of oral fast dissolving film of bisoprolol fumarate. Int J Pharm Drug Anal. 2018 Feb;6(2):105-15.
16. Jelvehgari M, Montazam SH, Soltani S, Mohammadi R, Azar K, Montazam SA. Fast dissolving oral thin film drug delivery systems consisting of ergotamine tartrate and caffeine anhydrous. Pharm Sci. 2015 Sep;21(2):102-10. doi: 10.15171/PS.2015.24.
17. Saleem MA, Naheed MD, Murali YD, Jaydeep P, Dhaval M. Preparation and evaluation of mupirucin loaded polymer composite films. J Drug Deliv Ther. 2012 May;2(3):167-72.
18Pallavi K, Pallavi T. Formulation and evaluation of fast dissolving films of eletriptan hydrobromide. Int J Curr Pharm Res. 2017 Jan;9(2):59-63. doi: 10.22159/ijcpr.2017v9i2.17386.
19. Sultana F, Arafat M, Pathan SI. Preparation and evaluation of fast dissolving oral thin film of caffeine. Int J Pharm Biol Sci. 2013 Jan;3(1):153-61.
20. Choudhary DR, Patel V, Patel H, Kundawala A. Formulation and evaluation of quick dissolving film of ondansetron hydrochloride. Int J Pharmacol Res. 2011 Dec;3(4):31-50.
21. Mushtaque M, Muhammad IN, Fareed Hassan SM, Ali A, Masood R. Development and pharmaceutical evaluation of oral fast dissolving thin film of escitalopram: A patient friendly dosage form. Pak J Pharm Sci. 2020 Jan;33(1):183-189. PMID: 32122847.
22. Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharm J. 2016 Sep;24(5):537-546. doi: 10.1016/j.jsps.2015.02.024. Epub 2015 Mar 10. PMID: 27752225; PMCID: PMC5059831.
23. Hoppe K, Sznitowska M. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media. AAPS PharmSciTech. 2014 Oct;15(5):1116-25. doi: 10.1208/s12249-014-0109-8. Epub 2014 May 29. PMID: 24871550; PMCID: PMC4179655.
24. Aparna C, Anusha M, Manisha B. Enhancement of dissolution of candesartan cilexetil. Asian J Pharm Clin Res. 2023 Mar;16(3):148-51. doi: 10.22159/ajpcr.2023.v16i3.46626.
25. Dizaj SM, Vazifehasl Zh, Salatin S, Adibkia Kh, Javadzadeh Y. Nanosizing of drugs: Effect on dissolution rate. Res Pharm Sci. 2015 Mar-Apr;10(2):95-108. PMID: 26487886; PMCID: PMC4584458.
26. Ghobad H, Cheraghali S. Effect of biocompatible polymers on the physicochemical properties of fenofibrate in nanoparticle system. J Chem Pharm Res. 2015;7(12):913-19.
27. Matteucci ME, Hotze MA, Johnston KP, Williams RO 3rd. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir. 2006 Oct 10;22(21):8951-9. doi: 10.1021/la061122t. PMID: 17014140.
28. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm. 2009 Jun 22;375(1-2):84-8. doi: 10.1016/j.ijpharm.2009.03.013. Epub 2009 Mar 24. PMID: 19481693.
29. Thadkala K, Nanam PK, Rambabu B, Sailu C, Aukunuru J. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability. Int J Pharm Investig. 2014 Jul;4(3):131-7. doi: 10.4103/2230-973X.138344. PMID: 25126526; PMCID: PMC4131384.
30. Thirupathi A, Reddy A, Narayana A, Meshram S, Sampathi S. Solid state characterization of the polymorphic changes in candesartan cilexetil solid dispersion with polyethylene glycol 8000. Int J Pharm Sci Res. 2014 Jun;5(6):2362-8. doi: 10.13040/IJPSR.0975-8232.5(6).2362-68.
31. Ashok Kumar U, Suresh G. Preparation and in vivo evaluation of candesartan cilexetil solid dispersions. Asian J Pharm Clin Res. 2021;14(8):129-33. doi: 10.22159/ajpcr.2021.v14i8.42037.
32. British Pharmacopoeia. Appendix XII C. Consistency of formulated preparations 4. Uniformity of dosage units. London (UK): The Stationery Office; 2011.
33. Saab M, Mehanna MM. Disintegration time of orally dissolving films: various methodologies and in-vitro/in-vivo correlation. Pharmazie. 2019 Apr 1;74(4):227-230. doi: 10.1691/ph.2019.8231. PMID: 30940306.
34. Mahesh R, Dabhi UK, Ghodasara DD, Mori KA, Manek R, Sheth NR. Formulation, optimization and characterization of candesartan cilexetil nanosuspension for in vitro dissolution enhancement. Afr J Pharm Pharmacol. 2015 Feb;9(5):102-13. doi: 10.5897/AJPP2013.3887.
Published
How to Cite
Issue
Section
Copyright (c) 2025 INAS F. ABDULRAZZAQ, MALATH H. OUDAH, ABULFADHEL AL-SHAIBANI, YASMIEN A. SALAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
